Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma | Zendy

Daisuke Murayama | Zendy; Soji Toda | Zendy; Yoichiro Okubo | Zendy; Hiroyuki Hayashi | Zendy; Ai Matsui | Zendy; Mio Yasukawa | Zendy; Hiroyuki Iwasaki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma

Author(s) -

Daisuke Murayama,

Soji Toda,

Yoichiro Okubo,

Hiroyuki Hayashi,

Ai Matsui,

Mio Yasukawa,

Hiroyuki Iwasaki

Publication year - 2021

Publication title -

case reports in endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.26

H-Index - 6

eISSN - 2090-6501

pISSN - 2090-651X

DOI - 10.1155/2021/3024639

Subject(s) - medicine , thyroid , sorafenib , thyroid carcinoma , follicular phase , lenvatinib , radioactive iodine , radiation therapy , oncology , endocrinology , thyroid cancer , hepatocellular carcinoma

Thyroid-associated ophthalmopathy (TAO) is an inflammation of the extraocular muscles and periorbital connective tissue caused by autoantibodies against common antigens to both the thyroid and orbit. The release of antigens and induction of hypothyroidism caused by radioactive iodine (RAI) therapy may exacerbate TAO. Here, we present the case of a 67-year-old-woman treated with RAI therapy for metastatic follicular thyroid carcinoma who presented with TAO during the course of sorafenib administration. Tg and TgAb levels were gradually decreased with sorafenib and lenvatinib treatment, and TAO was improved without any ophthalmologic treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research